Lanthanoid Series Elements

Lanthanoid Series Elements
Accession Number

Elements of the lanthanoid series including atomic number 57 (LANTHANUM) through atomic number 71 (LUTETIUM).

DrugDrug Description
Lanthanum carbonateA phosphate binder indicated for the reduction of serum phosphate in patients with end stage renal disease.
GadoliniumGadolinium is under investigation in Hypertension, ACUTE KIDNEY INJURY, and Chronic Kidney Disease. Gadolinium has been investigated for the basic science of CAD, Multiple Sclerosis, and Coronary Artery Disease.
SamariumSamarium has been used in trials studying the treatment and prevention of Pain, Cancer, Metastasis, Prostate Cancer, and Metastatic Osteosarcoma, among others.
NeodymiumNeodymium is under investigation in clinical trial NCT03525522 (Nd:Yttrium Aluminum Garnet Laser Treatment for Lichen Sclerosus).
GadoteridolA medication used to improve the contrast of MRI scans for better visualization.
EP-2104RInvestigated for use/treatment in cardiovascular disorders and thrombosis.
Gadofosveset trisodiumAn intravenous contrast agent used during magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with peripheral vascular disease.
Samarium Sm-153A radiopharmaceutical indicated in the treatment of bone pain in patients with skeletal metastases.
Lutetium Lu-177Not Annotated
GadopiclenolA gadolinium-based contrast agent (GBCA) used with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity.
AGuIXAGuIX is an investigational brand product consisting of a polysiloxane matrix and gadolinium chelates. It is under development as a radiosensitizer to be used during radiation treatment of malignant glioma.
Cerium dioxideNot Annotated
Drugs & Drug Targets
Lanthanum carbonatePhosphatetarget
EP-2104RFibrinogen alpha chaintarget
Gadofosveset trisodiumSerum albumincarrier